Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

The age groups tagged for this paper are older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Study endpoints included absolute serum 25(OH)D level at baseline, 12 months, and 24 months; change in serum 25(OH)D and bone mineral density (BMD) status from baseline; and incidence of new vertebral fractures at 24 months.

What Was Measured

Topics PubMed links to this paper include Bone Density, Bone Density Conservation Agents, Calcium, Denosumab, Spinal Fractures and Vitamin D.

Author keywords: Bone mineral density, Deficiency and Vitamin D insufficiency.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Journal of bone and mineral metabolism), a journal based in Japan.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.